Nedocromil
Based on 1 Customer Validation
Nedocromil (FPL 59002) is a mast cell stabilizer and an inhibitor of IL-8 production. Nedocromil inhibits mast cell degranulation and collagen synthesis induced by activated mast cells, indirectly interfering with IL-1β signaling. Nedocromil reduces conjunctival eosinophil infiltration and improves the cutaneous manifestations of chronic graft-versus-host disease (including reducing fibrosis, loss of fat and hair follicles, and inflammatory infiltration). Nedocromil can be used in research on chronic graft-versus-host disease, asthma, and allergic conjunctivitis.
商品は「研究用試薬」です。人や動物の医療用・臨床診断用・食品用の製品ではありません。
研究用途以外に使用した場合、当社は一切の責任を負いかねます。
- 純度 : 98.19%
- CAS 番号: 69049-73-6
- 分子式: C19H17NO7
- 分子量:371.34
-
保管条件:Powder -20°C, 3 years , 4°C, 2 years ; In solvent -80°C, 2 years , -20°C, 1 year
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
生物活性
-
化学情報
-
溶剤 & 溶解度
- プロトコル
- 純度とドキュメンテーション
- 参考文献
-
Help & FAQs
-
HY-14270
LodoxamideHistamine Receptor Inhibitor -
HY-13599
CladribineDNA Synthesis Inhibitor -
HY-14184
MacitentanETA/ETB Antagonist -
HY-U00027
Quinotolast sodium -
HY-13315
Montelukast sodiumCysltr1 Antagonist -
HY-13448R
Nedocromil (Standard)Reference Standard -
HY-U00364
CI-949 -
HY-13315R
Montelukast sodium (Standard)Cysltr1 Antagonist -
HY-16344
Nedocromil sodiumProstaglandin Receptor Inhibitor
生物活性
製品説明
IC50 & Target
[1]|
IL-1β |
IL-8 |
体外実験
Nedocromil sodium (10-5 mol/L; 4 h) prevents the increased expression of IL-8 mRNA induced by IL-1β in cultured human bronchial epithelial cells[2].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Cell Line:Human neutrophils and human bronchial epithelial cells
-
Concentration:up to 10^-5 mol/L
-
Incubation Time:8 h
-
Result:Did not significantly affect the chemotactic activity of epithelial cell-conditioned media at concentrations up to 10^-5 mol/L.
-
Cell Line:Human bronchial epithelial cells
-
Concentration:10^-5 mol/L (preincubation); 5 ng/mL (IL-1β)
-
Incubation Time:3-5 h (preincubation); 8 h (IL-1β stimulation)
-
Result:Reduced the release of immunoreactive IL-8 by >50% when added 3 to 5 hours before IL-1β.
Significantly reduced the release of immunoreactive IL-8 induced by IL-1β in a dose-dependent manner when preincubated for 4 hours.
Did not modify the constitutive release of IL-8 at concentrations up to 10^-5 mol/L.
体内実験
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:BALB/c (female, 6-10 weeks, 20-25 g)[1]
-
Dosage:5 mg/mouse
-
Administration:i.p.; daily; 15 days
-
Result:Decreased the mean dermis/fat ratio to 1.5 compared to 4.0 in saline-treated cGVHD mice.
Normalized skin mast cell numbers from 1.71 to 2.95.
Increased peritoneal mast cell numbers to 1.45 compared to 0.25 in controls.
臨床実験
| NCT Number | Sponsor | Condition | Start Date |
Phase
|
|---|---|---|---|---|
| NCT01329991 | 2011-05 | PHASE1 |
化学情報
-
CAS 番号 69049-73-6
-
性状 Solid
-
分子量 371.34
-
分子式 C19H17NO7
-
Color Light yellow to yellow
-
SMILES
O=C(C1=CC(C2=CC3=C(N(CC)C(C(O)=O)=CC3=O)C(CCC)=C2O1)=O)O
-
別名
FPL 59002
-
輸送条件
Room temperature in continental US; may vary elsewhere.
-
保管条件
Powder -20°C 3 years 4°C 2 years In solvent -80°C 2 years -20°C 1 year
溶剤 & 溶解度
体外:
DMSO : 16.67 mg/mL (44.89 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 2 years; -20°C, 1 year. When stored at -80°C, please use it within 2 years. When stored at -20°C, please use it within 1 year.
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 2 years; -20°C, 1 year. When stored at -80°C, please use it within 2 years. When stored at -20°C, please use it within 1 year.
濃度 (開始) × 体積 (開始) = 濃度 (終了) × 体積 (終了)
純度とドキュメンテーション
-
データシート (284 KB)
-
SDS (393 KB)
- English - EN (393 KB)
- Français - FR (393 KB)
- Deutsch - DE (393 KB)
- Norwegian - NO (393 KB)
- Español - ES (393 KB)
- Swedish - SV (393 KB)
- Italian - IT (393 KB)
- Korean - KR (393 KB)
- Portuguese - PT (393 KB)
-
取扱説明書 (2659 KB)
参考文献
Complete Stock Solution Preparation Table
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 2 years; -20°C, 1 year. When stored at -80°C, please use it within 2 years. When stored at -20°C, please use it within 1 year.
| Optional Solvent | Concentration Solvent Mass | 1 mg | 5 mg | 10 mg | 25 mg |
|---|---|---|---|---|---|
| DMSO | 1 mM | 2.6929 mL | 13.4647 mL | 26.9295 mL | 67.3237 mL |
| 5 mM | 0.5386 mL | 2.6929 mL | 5.3859 mL | 13.4647 mL | |
| 10 mM | 0.2693 mL | 1.3465 mL | 2.6929 mL | 6.7324 mL | |
| 15 mM | 0.1795 mL | 0.8976 mL | 1.7953 mL | 4.4882 mL | |
| 20 mM | 0.1346 mL | 0.6732 mL | 1.3465 mL | 3.3662 mL | |
| 25 mM | 0.1077 mL | 0.5386 mL | 1.0772 mL | 2.6929 mL | |
| 30 mM | 0.0898 mL | 0.4488 mL | 0.8976 mL | 2.2441 mL | |
| 40 mM | 0.0673 mL | 0.3366 mL | 0.6732 mL | 1.6831 mL |
Nedocromil 関連分類
HY-13448 関連分類
Powered by Bioz
Keywords
- Nedocromil
- 69049-73-6
- FPL 59002
- FPL59002
- FPL-59002
- Interleukin Related
- IL-1β-induced IL-8 production
- human bronchial epithelial cells
- asthma
- mast cell stabilizer
- skin mast cell numbers
- mast cell degranulation
- IL-8 mRNA
- allergic conjunctivitis
- chronic graft-versus-host disease
- human neutrophils
- Inhibitor
- inhibitor
- inhibit